###### Strengths and limitations of this study

-   This is a large observational study with secondary analysis of databases using a global database containing 184 countries.

-   Only countries with relatively good data quality are included in further analysis.

-   This study did not explore the clinical diversity of patients.

-   This is not a cohort study; therefore, the mortality and incident cases might not represent the same patients.

-   No information about survival time and survival rate was provided in this analysis.

Introduction {#s1}
============

Pancreatic cancer is a highly lethal disease, and most cases are usually detected in the advanced stages, after metastasis.[@R1] The incidence rates are currently increasing in the USA,[@R2] as well as in European countries, highlighting a rising trend worldwide for this disease that might be associated with improved diagnosis methods.[@R3] However, patients with advanced pancreatic cancer have limited treatment options, and fewer than 20% are candidates for surgery.[@R5] Consequently, the prognosis is poor for patients diagnosed with pancreatic cancer.

Many cancers differ in their incidence and mortality rates in specific countries, regions and continents across the globe, which raises the possibility that these differences could reflect regional healthcare disparities.[@R7] The aim of the present study was to use the mortality-to-incidence ratio (MIR) as a parameter for evaluating pancreatic cancer in different countries. The MIR is a measurement that compares the relationship between mortality and incidence, and its value can serve as a proxy for 1--survival.[@R11] Achieving low MIR values depends on adequate cancer screenings, early diagnosis and effective treatments by the healthcare system.[@R13] For example, Sunkara and Hebert, in their study on colorectal cancer, described the MIR as a useful indicator for cancer screening and care in patients with colorectal cancer, as they found a positive correlation between the MIR values and the healthcare system rankings for different countries.[@R10]

Pancreatic cancer, unlike colorectal cancer, is difficult to detect and lacks routine screening policies.[@R1] No evidence yet supports an association between cancer health disparities and the MIR of patients with this cancer. The objective of our study was therefore to evaluate the relationships between the incidence and mortality rates of pancreatic cancer and healthcare parameters, such as total expenditures on health/gross domestic product (e/GDP) and WHO rankings.

Materials and methods {#s2}
=====================

Data acquisition {#s2a}
----------------

Cancer epidemiological data were obtained from the GLOBOCAN 2012 database maintained by the International Agency for Research on Cancer (<https://www.iarc.fr/>). The WHO ranking for these countries was obtained from the World's Health Systems, maintained by WHO. The e/GDP, per capita total expenditure on health and life expectancies for 2012 were obtained from the World Health Statistics 2015, which is an annual compilation of health-related data for its 194 member states. In total, 184 countries were screened in the GLOBOCAN 2012 database. Among these, 25 countries were excluded since no matching data existed in the WHO database. We also excluded 102 countries according to the availability level rankings of the mortality and incidence data in the GLOBOCAN 2012 database; these excluded countries had availability level rankings of E--G for incidence or 4--6 for mortality. In total, 57 countries were ultimately analysed. The crude rate was defined as rate every 100 000 persons. The MIR, in the present study, was defined as the ratio of the crude rate of mortalities and the crude rate of incidences.[@R10]

Patient and public involvement {#s2b}
------------------------------

This study analysed GLOBOCAN 2012 database. Therefore, we did not inform or disseminate the patients about the research question, outcome measures and results. Patients did not involve in the study, including design, recruitment and conduct of the study. There was no patient adviser for contributorship statement.

Statistical analyses {#s2c}
--------------------

Associations between the MIRs and variants among countries were analysed by linear regression as described previously.[@R7] R^2^ changes and analysis of variance were analysed using SPSS statistical software version 15.0 (SPSS, Chicago, Illinois, USA). P values \<0.05 of two-sided tests were considered statistically significant. Scatter plots were generated via Microsoft Excel 2010.

Results {#s3}
=======

Rates of incidence/mortality and MIR of pancreatic cancer according to regions {#s3a}
------------------------------------------------------------------------------

The case numbers and rates of incidence and mortality for pancreatic cancer in different regions of the world are summarised in [table 1](#T1){ref-type="table"}. These regions were determined by three categories: development status, WHO region categories and continent. In this database, the incidence of pancreatic cancer is close in number (337 872 cases) to the number of mortalities (330 391 deaths). The world, as a whole, has a crude incidence rate of 4.8 and a crude mortality rate of 4.7. The age-standardised rates (ASRs) are 4.2 and 4.0 for incidence and mortality, respectively. The crude rates and ASRs of incidence and mortality are much larger in developed regions than in less developed regions ([table 1](#T1){ref-type="table"}). For the WHO region categories, the crude rates and ASRs of incidence and mortality are highest in the European region. Africa has the lowest crude rates and ASRs among the continents. The overall MIR is 0.98, and high MIRs occur in all regions ([table 1](#T1){ref-type="table"}).

###### 

Summary of the case numbers, rates and mortality-to-incidence ratio (MIR) of the incidence and mortality according to regions in pancreatic cancer

  Region                           Number    Crude rate   Age-standardised rate   MIR[\*](#tblfn1){ref-type="fn"}               
  -------------------------------- --------- ------------ ----------------------- --------------------------------- ----- ----- ------
  World                            337 872   330 391      4.8                     4.7                               4.2   4.0   0.98
  Development                                                                                                                   
   More developed regions          187 465   184 429      15.0                    14.8                              7.2   6.8   0.99
   Less developed regions          150 407   145 962      2.6                     2.5                               2.8   2.7   0.96
  WHO region categories                                                                                                         
   WHO Africa region               8324      8048         0.9                     0.9                               1.8   1.7   1.00
   WHO Americas region             75 094    73 751       7.9                     7.7                               5.9   5.6   0.98
   WHO East Mediterranean region   7686      7440         1.2                     1.2                               1.9   1.8   1.00
   WHO Europe region               110 499   111 029      12.2                    12.3                              6.5   6.4   1.01
   WHO South-East Asia region      23 210    21 638       1.3                     1.2                               1.5   1.4   0.92
   WHO Western Pacific region      113 015   108 444      6.1                     5.9                               4.4   4.1   0.97
  Continent                                                                                                                     
   Africa                          12 101    11 704       1.1                     1.1                               2.0   1.9   1.00
   Latin America and Caribbean     27 723    27 935       4.6                     4.6                               4.4   4.4   1.00
   Northern America                47 371    45 816       13.5                    13.1                              7.4   6.9   0.97
   Asia                            143 363   137 251      3.4                     3.2                               3.2   3.0   0.94
   Europe                          103 845   104 554      14.0                    14.1                              6.8   6.6   1.01
   Oceania                         3469      3131         9.2                     8.3                               5.9   5.2   0.90

\*The percentage in the ratio of the crude rate of mortalities and the crude rate of incidences.

Rates of incidence/mortality and MIR of pancreatic cancer according to countries {#s3b}
--------------------------------------------------------------------------------

In total, 57 countries were included according to the criteria in this study ([figure 1](#F1){ref-type="fig"}). [Table 2](#T2){ref-type="table"} summarises the incidence and mortality according to country. The USA has the highest case number among the 57 countries. Four countries have a crude rate of incidence greater than 20: Japan (26.0), Finland (21.3), Germany (20.1) and the Czech Republic (20.0). These countries are also among the five that have crude mortality rates over 18, with the other one being Slovenia (18.3). The Czech Republic shows the highest ASR in both incidence and mortality (9.7 and 8.7, respectively).

![Diagram for data source selection.](bmjopen-2017-020618f01){#F1}

###### 

Summary of WHO rankings, total expenditure on health/gross domestic product (GDP), life expectancy, pancreatic cancer incidence, mortality and mortality-to-incidence ratio (MIR) of selected countries

  Country                  Ranking   Total expenditure on health/GDP (%)   Life expectancy   Number   Crude rate   Age-standardised rate   MIR[\*](#tblfn2){ref-type="fn"}               
  ------------------------ --------- ------------------------------------- ----------------- -------- ------------ ----------------------- --------------------------------- ----- ----- ------
  France                   1         11.6                                  82                9149     9588         14.4                    15.1                              6.9   6.5   1.05
  Italy                    2         9.2                                   83                10 688   10 637       17.5                    17.4                              6.7   6.4   0.99
  Malta                    5         8.7                                   81                75       60           17.9                    14.3                              8.1   6.6   0.80
  Singapore                6         4.2                                   83                404      451          7.7                     8.6                               5.1   5.6   1.12
  Spain                    7         9.3                                   83                6367     5720         13.6                    12.2                              6.3   5.5   0.90
  Oman                     8         2.7                                   76                35       36           1.2                     1.2                               2.2   2.3   1.00
  Austria                  9         11.1                                  81                1585     1486         18.8                    17.6                              8.2   7.3   0.94
  Japan                    10        10.3                                  84                32 899   31 046       26.0                    24.6                              8.5   7.7   0.95
  Norway                   11        9.3                                   82                735      696          14.8                    14.0                              7.2   6.6   0.95
  Portugal                 12        9.9                                   81                1225     1268         11.4                    11.9                              5.0   4.9   1.04
  Iceland                  15        9.0                                   82                29       29           8.8                     8.8                               5.0   5.0   1.00
  Luxembourg               16        7.2                                   82                67       67           12.8                    12.8                              6.1   6.0   1.00
  Netherlands              17        12.7                                  81                2141     2489         12.8                    14.9                              6.3   6.7   1.16
  UK                       18        9.3                                   81                8747     8406         13.9                    13.4                              6.3   5.9   0.96
  Ireland                  19        8.9                                   81                510      488          11.1                    10.7                              6.6   6.2   0.96
  Switzerland              20        11.4                                  83                1172     1080         15.2                    14.0                              6.5   5.8   0.92
  Belgium                  21        10.9                                  80                1293     1596         12.0                    14.8                              5.7   5.9   1.23
  Colombia                 22        6.8                                   78                1643     1617         3.5                     3.4                               3.8   3.7   0.97
  Sweden                   23        9.6                                   82                964      1640         10.2                    17.3                              4.8   7.0   1.70
  Cyprus                   24        7.3                                   82                77       88           6.8                     7.8                               4.3   4.9   1.15
  Germany                  25        11.3                                  81                16 451   16 188       20.1                    19.7                              7.9   7.3   0.98
  Israel                   28        7.4                                   82                862      867          11.2                    11.3                              7.6   7.3   1.01
  Canada                   30        10.9                                  82                4472     4293         12.9                    12.4                              6.4   5.9   0.96
  Finland                  31        9.1                                   81                1151     1052         21.3                    19.5                              8.7   7.8   0.92
  Australia                32        8.9                                   83                2864     2537         12.5                    11.1                              6.6   5.6   0.89
  Chile                    33        7.3                                   80                1152     1246         6.6                     7.2                               4.8   5.2   1.09
  Denmark                  34        11.0                                  80                1023     877          18.3                    15.7                              8.5   7.1   0.86
  Costa Rica               36        10.1                                  79                210      178          4.4                     3.7                               4.1   3.5   0.84
  USA                      37        17.0                                  79                42 885   41 509       13.6                    13.1                              7.5   7.0   0.96
  Slovenia                 38        9.4                                   80                383      374          18.8                    18.3                              8.8   8.1   0.97
  Cuba                     39        8.6                                   78                895      944          8.0                     8.4                               4.6   4.7   1.05
  New Zealand              41        10.2                                  82                486      476          10.9                    10.7                              5.9   5.6   0.98
  Bahrain                  46        4.4                                   77                21       18           1.5                     1.3                               2.9   2.7   0.87
  Thailand                 47        4.5                                   75                1920     1722         2.7                     2.5                               2.1   1.8   0.93
  Czech Republic           48        7.5                                   78                2118     1928         20.0                    18.2                              9.7   8.7   0.91
  Malaysia                 49        4.0                                   74                594      774          2.0                     2.6                               2.4   3.2   1.30
  Poland                   50        6.8                                   77                5004     4846         13.1                    12.6                              6.9   6.6   0.96
  Jamaica                  53        5.6                                   74                104      104          3.8                     3.8                               3.3   3.5   1.00
  Republic of Korea        58        7.6                                   82                5379     5086         11.1                    10.5                              6.7   6.2   0.95
  Philippines              60        4.4                                   69                1682     1476         1.7                     1.5                               2.6   2.4   0.88
  Slovakia                 62        8.1                                   76                881      815          16.1                    14.9                              9.4   8.5   0.93
  Egypt                    63        4.9                                   71                2347     2268         2.8                     2.7                               3.4   3.3   0.96
  Uruguay                  65        8.6                                   77                454      480          13.4                    14.2                              7.7   7.9   1.06
  Trinidad and Tobago      67        5.5                                   71                93       88           6.9                     6.5                               6.1   5.8   0.94
  Belarus                  72        5.0                                   72                809      836          8.5                     8.8                               5.0   5.1   1.04
  Lithuania                73        6.7                                   74                480      458          14.6                    13.9                              7.4   6.9   0.95
  Argentina                75        6.8                                   76                3988     4330         9.7                     10.5                              6.7   7.2   1.08
  Estonia                  77        5.9                                   77                191      229          14.3                    17.1                              7.0   7.5   1.20
  Ukraine                  79        7.5                                   71                4728     4168         10.5                    9.3                               5.9   5.3   0.89
  Mauritius                84        4.8                                   74                60       78           4.6                     5.9                               3.9   5.1   1.28
  Fiji                     96        4.0                                   70                17       17           1.9                     1.9                               2.1   2.2   1.00
  Bulgaria                 102       7.4                                   75                1236     1052         16.7                    14.2                              8.0   6.7   0.85
  Latvia                   105       5.9                                   74                371      366          16.6                    16.4                              8.1   7.4   0.99
  Ecuador                  111       6.4                                   76                458      522          3.1                     3.5                               3.2   3.6   1.13
  Brazil                   125       9.5                                   75                9871     9879         5.0                     5.0                               4.6   4.5   1.00
  Russian Federation       130       6.5                                   69                14 512   16 371       10.2                    11.5                              6.0   6.7   1.13
  South African Republic   175       8.9                                   60                1830     1768         3.6                     3.5                               4.7   4.6   0.97

\*The percentage in the ratio of the crude rate of mortalities and the crude rate of incidences.

The calculated MIRs are also presented in [table 2](#T2){ref-type="table"}. Malta has the lowest MIR among the 57 countries. Eighteen countries have MIRs greater than 1.00, with Sweden having the highest MIR. Eight countries have MIRs below 0.90, including Malta (0.80), Costa Rica (0.84), Bahrain (0.87), Bulgaria (0.85), Denmark (0.86), the Philippines (0.88), Ukraine (0.89) and Australia (0.89).

The associations between WHO ranking, e/GDP, per capita total expenditure on health and life expectancy among countries {#s3c}
-----------------------------------------------------------------------------------------------------------------------

The WHO ranking, e/GDP and life expectancy among the different countries are also listed in [table 2](#T2){ref-type="table"}. Linear regression confirms that countries with better WHO rankings have a high e/GDP (p=0.012, online [supplementary figure S1A](#SP1){ref-type="supplementary-material"}). A similar relationship is evident between the WHO ranking and life expectancy (p\<0.001, online [supplementary figure S1B](#SP1){ref-type="supplementary-material"}). Countries with better WHO rankings are more likely to have higher e/GDP and a longer life expectancy.
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The associations between crude rates and ASRs of incidence and mortality to the WHO ranking and to e/GDP are demonstrated in online [supplementary figures S2 and S3](#SP1){ref-type="supplementary-material"}. Countries with better WHO rankings are more likely to have higher incidence and mortality crude rates, but the ASR shows no statistical significance (online [supplementary figures S2A--S2D](#SP1){ref-type="supplementary-material"}). Countries with higher e/GDP also have higher incidence and mortality crude rates and ASRs (online [supplementary figures S3A--S3D](#SP1){ref-type="supplementary-material"}). Interestingly, no significant correlations are observed between WHO ranking, e/GDP and MIR (WHO ranking: R^2^=0.001, p=0.818, e/GDP: R^2^=0.006, p=0.553), as shown in [figure 2](#F2){ref-type="fig"}. This is further confirmed via using per capita total expenditure on health for analysis. The list of per capita total expenditure on health of selected countries is shown in online [supplementary table 1](#SP1){ref-type="supplementary-material"}. As shown in [figure 3](#F3){ref-type="fig"}, the MIR is not significantly correlated with per capita total expenditure on health.

![The (A) WHO rankings and (B) total expenditures on health/gross domestic product (GDP) were not associated with the mortality-to-incidence ratio (MIR) of pancreatic cancer.](bmjopen-2017-020618f02){#F2}

![The per capita total expenditure on health in (A) US\$ and (B) purchasing power parity at international dollar rate (PPP) were not associated with the mortality-to-incidence ratio (MIR) of pancreatic cancer.](bmjopen-2017-020618f03){#F3}

Discussion {#s4}
==========

To our knowledge, this is the first study to investigate the associations between the MIR of pancreatic cancer, the WHO ranking, life expectancy and e/GDP. We found no correlation between MIRs and WHO rankings or between MIRs and e/GDP. These findings differ from those reported previously for colorectal cancer, where a positive correlation was found between the healthcare system rankings and MIRs.[@R10] This discrepancy probably reflects the different characteristics and natural courses of these two cancers. Colorectal cancer is easier to screen with faecal immunochemical testing, fecal occult blood tests(FOBTs) or colonoscopy and it is a slowly developing cancer, taking years to develop from polyps.[@R16] The screening methods and long duration of cancer development allow early detection of the disease, as reflected by a higher worldwide incidence rate and an early diagnosis.[@R10] Pancreatic cancer, by contrast, has no efficient screening methods comparable with those available for colorectal cancer.[@R14] The sole screening method that is accessible to the public consists of the CA-199 biomarker, which, unfortunately, has a poor sensitivity and specificity since many non-malignant diseases also increase its level.[@R17]CT is also not sufficiently sensitive for detecting early pancreatic cancer.[@R19] The lack of screening and early detection strategies, even in highly developed regions, results in advanced cancer stage at diagnosis, with 55% of the cases being diagnosed at stage IV.[@R20] Consistently high MIRs across global regions are therefore inevitable, as approximately 95% of the cases die within 5 years after diagnosis.[@R20]

Conversely, we found negative correlations between the WHO ranking and the e/GDP, life expectancy and incidence and mortality crude rates for pancreatic cancer, meaning that the numbers for these categories would increase as the WHO rankings improved. We also found positive correlations between the crude rates of mortality and incidence and the e/GDP.[@R7] One possible explanation for this latter finding is that this disease usually strikes the elderly, with most cases diagnosed at ages 60--80.^3^ Our finding of a negative correlation between the WHO ranking and life expectancy, as shown in online [supplementary figure S1](#SP1){ref-type="supplementary-material"}, indicates that those countries with better WHO rankings, where the citizens are more likely to have longer life expectancies, also have a higher incidence of this cancer. Another explanation could be the variability in healthcare accessibility among countries with different WHO rankings. Countries with worse rankings are more likely to have poorer healthcare access. Thus, signs and symptoms of pancreatic cancer may be overlooked, thereby causing a decrease in the incidence rate relative to the total cases who die with undiagnosed pancreatic cancer. This will reduce the reported cases both in incidence and in mortality and result in misleading of apparently lower crude rates.

The MIR was calculated with the crude rate ratio of mortality and incidence. In total, 18 countries had MIR values greater than 1.00, which would not happen in a cohort study. However, the GLOBOCAN database, which provides contemporary estimates of the cancer incidence, mortality and prevalence, is not a cohort study. Other factors, such as control of the denominator time, underestimation of cancer incidence and database quality, might account for this issue.[@R23] Therefore, we excluded countries with poor or unknown availability data according to the ranking of GLOBOCAN 2012 to reduce the information and data bias.

Our study has a large sample size, but it still has some limitations. The GLOBOCAN database collected data from various countries to observe cancer epidemiology. The data were also scored according to the quality of data acquisition. We did not include those countries with poor or unknown availability of mortality/incidence data to reduce the bias, which leads to incompleteness of the data collection and reduces the generalisability of the results. Moreover, patients with early disease might not be diagnosed and not be included in this database. We also did not record the risk factors among countries, such as smoking percentage, long-term diabetes mellitus and chronic pancreatitis, and these risk factors may play important roles in determining the incidence and mortality rates among different countries and regions.[@R24] We also only collected cross-sectional data for 1 year, so the data may not accurately present the actual trend of the disease. Another limitation is the use of WHO ranking: this grading system was established in 2000, so it may not precisely reflect the current situation for healthcare systems among different countries, although the correlations with life expectancy and e/GDP assure some of its credibility. Despite these limitations, our study shows higher incidence and mortality rates of pancreatic cancer in more developed regions and countries with better WHO rankings. However, the MIRs of the countries seem to have no association with their WHO rankings and e/GDP.
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